NEW YORK, April 2 - Japan's National Cancer Center will use Third Wave's Invader technology to genotype more than 100,000 genetic variations among several hundred individuals in a study to better understand the genetic foundations of cancer.
Terms of the agreement call for Third Wave to provide the NCC with access to the Invader system as well as undisclosed "collaborative support" for the study. In return, Third Wave will receive an initial multi-million dollar payment from the cancer center as well as follow-on product sales and the ability to license any discoveries that arise from the study.
Other financial details were not released.
The NCC was established in 1962 as the only national government-supported cancer center in Japan. It comprises two research facilities and two hospitals that serve more than 500,000 cancer patients each year, according to the NCC.